Provided by Tiger Trade Technology Pte. Ltd.

KEYMED BIO-B

73.050
-0.500-0.68%
Volume:2.62M
Turnover:191.18M
Market Cap:21.84B
PE:-38.25
High:74.800
Open:73.500
Low:71.000
Close:73.550
52wk High:89.750
52wk Low:44.660
Shares:299.00M
HK Float Shares:299.00M
Volume Ratio:1.75
T/O Rate:0.88%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.910
ROE:21.49%
ROA:-8.24%
PB:4.66
PE(LYR):-38.25
PS:22.39

Loading ...

The Bull Case For Keymed Biosciences (SEHK:2162) Could Change Following Key Phase III Oncology Success

Simply Wall St.
·
Aug 06

Asset Manager Raises Stake in KEYMED BIO-B with HK$14.8 Million Purchase

Stock News
·
Aug 04

Movement Alert|KEYMED BIO-B Falls 5.38% in Regular Trading, CMG901 Phase III Positive Data Triggers Sell-the-News Pressure

Market Focus
·
Jul 29

Hong Kong Stocks Edge Higher Ahead of Central Bank Meetings; Keymed Biosciences Falls

MT Newswires Live
·
Jul 28

Movement Alert|KEYMED BIO-B Falls 5.59% in Regular Trading, CMG901 Phase 3 Success Triggers Sell-the-News Reaction

Market Focus
·
Jul 28

Keymed Biosciences' Gastric Cancer Drug Meets Phase 3 Goal; Shares Fall 5%

MT Newswires Live
·
Jul 28

Keymed Biosciences Says CLARITY-Gastric01 Phase III Trial Achieves Positive Topline Results

Reuters
·
Jul 28

KeyMed Biosciences - Trial Meets Dual Primary Endpoints for Overall Survival in Advanced Gastric Cancer

THOMSON REUTERS
·
Jul 28

KeyMed Biosciences - Clarity-Gastric01 Phase Iii Trial Achieves Positive Topline Results

THOMSON REUTERS
·
Jul 28

Hong Kong Stocks Rise on Thursday; Tsaker New Energy Soars

MT Newswires Live
·
Jul 23

Keymed Bio-B Shares Surge Over 3% Following Inclusion of CM512 in China's Breakthrough Therapy Designation List

Stock News
·
Jul 23

KEYMED BIO-B's CM512 Designated as Breakthrough Therapy for Chronic Rhinosinusitis with Nasal Polyps

Stock News
·
Jul 23

Keymed Biosciences Advances Phase II Trials for CM512 Across Multiple Respiratory and Inflammatory Indications

Reuters
·
Jul 23

Keymed Biosciences Says China Regulator Grants Breakthrough Therapy Designation for CM512 in Crswnp

Reuters
·
Jul 23

Keymed Biosciences - Cm512 Included in Breakthrough Therapy Designation List for Chronic Rhinosinusitis with Nasal Polyps

THOMSON REUTERS
·
Jul 23

HK Movers | Biomedical Stocks Rally; REMEGEN, WUXI XDC and KEYMED BIO-B Surge Over 8%

Tiger Newspress
·
Jul 20

Movement Alert|Keymed Biosciences Rises 7.1% in Regular Trading, Profit Alert and Sector-Wide Institutional Buying Boost Shares

Market Focus
·
Jul 20

Movement Alert|Keymed Biosciences Drops 5.12% in Regular Trading, Biotech Sector Broadly Weakens After Prior Catalysts Priced In

Market Focus
·
Jul 17

Keymed Biosciences Inc. (HKG:2162) About To Shift From Loss To Profit

Simply Wall St.
·
Jul 16

Keymed Biosciences Expects H1 Profit at Least RMB 1.2 Billion

Reuters
·
Jul 15